All stocks / VXRT
Vaxart, Inc. VXRT
Vaxart (VXRT): financing deals mentioned in an 8-K in April 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- VAXART INC
- Market tier
- OTCQX US
- Trading status
- Active
- Last trade
- 09:57:11
- Website
- www.vaxart.com
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Revenue
- $237,258,000
- Net income
- $16,327,000
It earned more than it spent
SteadyAfter all costs, the company kept $16.3 million as profit in the year.
- Cash and cash equivalents
- $53,814,000
- Net cash from operating activities
- $7,714,000
The business brings in cash
SteadyDay-to-day business added $7.7 million in cash over the year. It had $53.8 million in the bank.
- Total assets
- $186,079,000
- Total liabilities
- $98,281,000
It owns more than it owes
SteadyEverything the company owns adds up to $186.1 million. Its debts and unpaid bills add up to $98.3 million. That is about $0.53 owed for every $1 owned.
What this adds up to
0 of 3 checks show strain. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 237,302,740 shares as of 2026-10-30: 243,702,034 outstanding minus 6,399,294 held by 11 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
8-K filed 2026-04-17 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about VXRT
Does VXRT file reports with the SEC?
Yes. Vaxart files with the SEC under company number 0000072444. The most recent filing we hold is a 8-K dated 2026-11-05.
Source recordHow many VXRT shares are outstanding?
243,702,034 shares as of 2026-10-30, as reported to the SEC.
Source recordHas VXRT filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs Vaxart?
Officers named in its insider filings: Edward B Berg (SVP, General Counsel), James F. Cummings (Chief Medical Officer) and Jeroen Nicolaas Grasman (Chief Financial Officer).
Source recordIs Vaxart making money?
After all costs, the company kept $16.3 million as profit in the year. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record